68Ga-P3 PET/CT Imaging in Prostate - Trial NCT05940259
Access comprehensive clinical trial information for NCT05940259 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Recruiting. The study focuses on Neoplasms. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University First Hospital
Timeline & Enrollment
N/A
May 29, 2023
Jul 31, 2025
Primary Outcome
The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate,The detection efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate
Summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that
 consists of 750 amino acids. It is highly expressed on most prostate cancer cells and
 neovascular endothelial cells of tumors, making PSMA a highly specific and significant
 imaging target for malignancies.
 
 [68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the
 diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05940259
Non-Device Trial